Shanghai Sanyou Medical Co., Ltd (688085.SH): Implanet and CHU Amiens Picardie conduct clinical cooperation research and complete the first multi-arm spinal surgery in Europe with Siasun Robot & Automation installation.
San You Medical (688085.SH) announced that its controlling company, French company Implanet, has established a research and clinical partnership with the Amiens-Picardie University Medical Center ("CHU Amiens Picardie") in France to jointly conduct clinical evaluation studies and obtain EU CE certification for the world's first multi-arm humanoid intelligent surgical robot in the field of spinal surgery, named Chunfenghuayu 8i Robotics. The installation work for the first multi-arm humanoid intelligent spinal surgery robot has been completed in Europe.
Shanghai Sanyou Medical Co., Ltd (688085.SH) announced that its controlling company, Implanet, in France, has established a research and clinical partnership with the Amiens Picardie University Medical Center (referred to as "CHU Amiens Picardie") in France for the robotic surgery system, Siasun Robot&Automation. They will collaborate on the global first multi-arm humanoid intelligent surgery system in the field of spinal surgery. The system has already completed the installation of the first multi-arm humanoid intelligent spinal surgery system in Europe.
This installation marks the beginning of a series of research and clinical work in spinal and neurological surgery in Europe. The advanced electromagnetic navigation, integrated digital microscope technology, and multi-arm collaborative ultrasonic bone knife technology of the Siasun Robot&Automation system will be validated in a complex clinical environment in Europe. At present, Siasun Robot&Automation's multi-arm humanoid intelligent surgery system has been installed in five hospitals in North America, Asia, and Europe for research and clinical purposes.
Related Articles

TRULY INT'L (00732) bought back 1 million shares for $900,000 Hong Kong dollars on July 17th.

Liaoning Chengda Biotechnology (688739.SH): Influenza Virus Split Vaccine (High Dose) Enters Phase I Clinical Trial.

B&K CORP-B(02396) has changed its Chinese name to "Qingcheng New Medicine Biotechnology (Qingdao) Co., Ltd."
TRULY INT'L (00732) bought back 1 million shares for $900,000 Hong Kong dollars on July 17th.

Liaoning Chengda Biotechnology (688739.SH): Influenza Virus Split Vaccine (High Dose) Enters Phase I Clinical Trial.

B&K CORP-B(02396) has changed its Chinese name to "Qingcheng New Medicine Biotechnology (Qingdao) Co., Ltd."

RECOMMEND





